Gene · 7306
Papers3,635
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 3,635
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| In Vitro, Ex Vivo and Clinical Trial of Brightening Serum Using a Novel Delivery System on Subjects With Moderate to Severe Dyschromia. | J Cosmet Dermatol | 2026 | 41645545 | PubTator, text mining | PubMed |
| Hydroxypinacolone 9-cis retinoate mitigates UV-induced photoaging by modulating extracellular matrix, fibroblasts, inflammation, and melanogenesis. | J Invest Dermatol | 2026 | 41644086 | PubTator, text mining | PubMed |
| In vivo engineering of CAR-T cells: delivery strategies and clinical translation. | Biomark Res | 2026 | 41593732 | PubTator, text mining | PubMed |
| Peroxisome Membrane Protein PEX16 Inhibits Melanogenesis by Inhibiting the Wnt/β-Catenin Signalling Pathway. | Exp Dermatol | 2026 | 41518585 | PubTator, text mining | PubMed |
| A model for de novo pigmentation of amelanotic retinal pigment epithelial cells. | Acta Ophthalmol | 2026 | 40892030 | PubTator, text mining | PubMed |
| Molecular docking and dynamics simulations of 4-heteroarylidenamino-4,5-dihydro-1H-1,2,4-triazol-5-one derivatives as potential anticancer agents. | Comput Biol Chem | 2026 | 40886663 | PubTator, text mining | PubMed |
| Extracellular vesicles in cancer immunotherapy: Therapeutic, challenges and clinical progress. | Asian J Pharm Sci | 2025 | 41809263 | PubTator, text mining | PubMed |
| Current Therapies and Potential Strategies for Uveal Melanoma. | Drugs Drug Candidates | 2025 | 41737289 | PubTator, text mining | PubMed |
| Temporal dynamics & determinants of antibiotic resistance gene profiles in the infant gut during the first year of life. | Indian J Med Res | 2025 | 41648984 | PubTator, text mining | PubMed |
| Exploring the Link Between PACAP Signalling and Hyaluronic Acid Production in Melanoma Progression. | Int J Mol Sci | 2025 | 41465475 | PubTator, text mining | PubMed |
| Mechanistic Insights into Anti-Melanogenic Effects of Fisetin: PKCα-Induced β-Catenin Degradation, ERK/MITF Inhibition, and Direct Tyrosinase Suppression. | Int J Mol Sci | 2025 | 41373883 | PubTator, text mining | PubMed |
| Germline DNA Repair and Immune-metabolic Alterations Suggest a Potentially Distinct Form of Early-onset Prostate Cancer in Men of African Descent. | Eur Urol Oncol | 2025 | 41350179 | PubTator, text mining | PubMed |
| Abstracts of the Annual Conference of the German Society for Biological Radiation Research (DeGBS) : Munich, Germany. 29 September-1 October 2025. | Radiat Oncol | 2025 | 41254773 | PubTator, text mining | PubMed |
| Enhanced degradation of sulfamethazine by Achromobacter via oxygenation through co-metabolism. | J Environ Manage | 2025 | 41197485 | PubTator, text mining | PubMed |
| Metagenomic analysis reveals the abundance changes of bacterial communities and antibiotic resistance genes in the influent and effluent of hospital wastewater. | PLoS One | 2025 | 41171744 | PubTator, text mining | PubMed |
| A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors. | Clin Cancer Res | 2025 | 41071338 | PubTator, text mining | PubMed |
| Amino Acid Metabolism of the Skin: Control by Specific Enzymes and Contribution to Protective Functions. | Metabolites | 2025 | 41002986 | PubTator, text mining | PubMed |
| mRNA Multipeptide-HLA Class II Immunotherapy for Melanoma. | Cells | 2025 | 41002395 | PubTator, text mining | PubMed |
| From paleness to albinism: Contribution of OCA2 exon 10 skipping to hypopigmentation. | PLoS Genet | 2025 | 40996958 | PubTator, text mining | PubMed |
| Proteome-wide Mendelian randomization and colocalization analysis identify therapeutic targets for cutaneous melanoma. | Medicine (Baltimore) | 2025 | 40988203 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7306/papers?page=3